Genomic detection of human immunodeficiency virus (HIV) by nucleic acid amplification test in a frequent platelet donor during the pre-seroconversion period

Archives of Virology

Volumn 156, Issue 11, 2011, Pages 2085-2090

  de Pondé, Robério Amorim Almeida ^a,b,c  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b Central Goiana de Sorologia Imuno hematologia e Biologia Molecular   (Brazil)

^c Hospital Materno Infantil   (Brazil)

Author keywords

Blood donation; HIV diagnosis; Nucleic acid testing; p24; Window period

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD DONOR; BLOOD SAFETY; CASE REPORT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; NUCLEIC ACID AMPLIFICATION; THROMBOCYTE; VIROLOGY;

ADULT; BLOOD DONORS; BLOOD PLATELETS; BLOOD SAFETY; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80355132088     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1085-x     Document Type: Article

References (38)

1. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML (2000) Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 284(2): 210-214.
2. Bush MP, Satten GA (1997) Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 102: 117-124.
3. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B (1994) Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 34(4): 283-289.
4. Busch MP, Glynn S, Stramer S, Strong M, Caglioti S, Wright D, Pappalardo B, Kleinman S (2005) A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45: 254-264.
5. Phelps R, Robbins K, Liberti T, Machuca A, Leparc G, Chamberland M, Kalish M, Hewlewtt I, Folks T, Lee L, McKenna M (2004) Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 44: 929-933.
6. Wendel S, Fachini R, Levi J, Ghaname J, Mendonça M, Almeida C, DiPietro A (2002) A single window-period donation detected by human immunodeficiency vírus p24 antigen after 5 years of routine screening in a group of Brazilian blood Banks. Vox sanguinis 83: 309-312.
7. van de Laar MJ, Likatavicius G, Stengaard AR, Donoghoe MC (2008) HIV/AIDS surveillance in Europe: update 2007. Euro Surveill 13(50)pii: 19066.
8. Kilmarx PH (2009) Global epidemiology of HIV. Curr Opin HIV AIDS 4(4): 240-246.
9. Scully C, Greenspan J (2006) Human immunodeficiency virus (HIV) transmission in dentistry. J Dent Res 85(9): 794-800.
10. McCarthy GM, Ssali CS, Bednarsh H, Jorge J, Wangrangsimakul K, Page-Shafer K (2002) Transmission of HIV in the dental clinic and elsewhere. Oral Diseases 8(Suppl 2): 126-135.
11. Hutin YJ, Harpaz R, Drobenniuc J (1999) Injections given in healthcare setting as a major source of acute hepatitis B in Moldona. Int J Epidemiol 28: 782-786.
12. Kane M (1998) Unsafe injections. Bull World Health Organ 76: 99-100.
13. Hersh BS, Popovici F, Jezek Z (1993) Risk Factors of HIV infections among abandoned Romanian children. AIDS 7: 1617-1624.
14. Bautista LE, Orostegui M (1997) Dental care associated with an outbreak of HIV infection among dialysis patients. Rev Panam Salud Publica 2: 194-202.
15. DePaola D, Howell H, Baker CG, Boy-Lefevre ML, Hull P, Holmstrup P, Jerolimov V, Hardwick K, Lamster IB, Lopez NL (2002) Research and the dental student. Eur J Dental Educ 6(Suppl 3): 45-51.
16. Kohn WG, Collins AS, Cleveland JL, Harte JA, Eklund KJ, Malvitz DM (2001) Guidelines for infection control in dental Health-Care setting. MMWR 52(RR-17): 1-61.
17. Nasir EF, Astrom AN, David J, Ali RW (2009) Utilization of dental health care services in context of the HIV epidemic-a cross-sectional study of dental patients in the Sudan. BMC Oral Health 9: 30.
18. Piquet Y, Ivanovic Z, Laperche S, Pillonel J, Cristol G, Jeanne M, Neaus D, Fleury H, Boiron JM (2007) Nucleic acid amplification testing detecting of an HIV-1 infection in a blood donor during the preseroconversion window period. Transfusion 17: 147-148.
19. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S (2007) Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Meth 143: 86-94.
20. Pandori M, Branson B (2010) 2010 HIV Diagnostics conference. Expert Rev Anti Infect Ther 8(6): 631-633.
21. Berrey MM, Schlaker T, Collier AC, Shea T, Brodie SJ, Mayers D, Coombs R, Krieger J, Chun TW, Fauci A, Self SG, Corey L (2001) Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 183: 1466-1475.
22. Ly TD, Laperche S, Brennan C, Vallari A, Ebel A, Hunt J, Martin L, Daghfal D, Schochetman G, Devare S (2004) Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Meth 122: 185-194.
23. Sudha T, Lakshmi V, Teja VD (2006) Western blot profile in HIV infection. Ind J Dermatol Venereol Leprol 72(5): 357-360.
24. Duri K, Müller F, Gumbo FZ, Kurewa NE, Rusakaniko S, Chirenje MZ, Mapingure MP, Stray-Pedersen B (2011) Human Immunodeficiency Virus (HIV) types Western blot (WB) band profiles as potential surrogate markers of HIV disease progression and predictors of vertical transmission in a cohort of infected but antiretroviral therapy naïve pregnant women in Harare, Zimbabwe. BMC Infect Dis 11: 7.
25. Tobler LH, Kaufman E, Gefter N, Schable C, Busch MP (1997) Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening. Transfusion 37(9): 921-925.
26. Ravanshad M, Sabahi F, Mahboudi F, Kazemnejad A (2006) Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens. Saudi Med J 27(1): 31-36.
27. Stramer SL (2002) US NAT yield. Where are we after 2 years? Transf Med 12: 243-253.
28. Grant PR, Busch MP (2002) Nucleic acid amplification technology methods used in blood donor screening. Transf Med 12: 229-242.
29. Roth WK, Weber M, Seifried E (1999) Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood-bank setting. Lancet 353: 359-363.
30. Aprili G, Gandini G, Piccoli P, Bressan F, De Gironcoli M, Mazzi R, Parisi S, Gessoni G, Marchiori G, Franchini M (2003) Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period. Transfusion 43: 848-852.
31. Candotti D, Richetin A, Cant B, Temple J, Sims C, Reeves I, Barbara J, Allain J-P (2003) Evaluation of a transcription-mediated amplification-based HCV and HIV-1 duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 43: 215-225.
32. Najioullah F, Barlet V, Renaudier P, Guitton C, Crova P, Guérin J-C, Peyramond D, Trabaud M-A, Coudurier N, Tardy J-C, André P (2004) Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol 73: 347-349.
33. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RC, Busch MP (2004) First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sanguinis 86: 171-177.
34. Tabor E, Epstein JS (2002) NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 42(9): 1230-1237.
35. Roth WK, Weber M, Buhr S (2002) Yield of HCV and HIV-1 NAT after screening of 3, 6 million blood donations in central Europe. Transfusion 42: 862-868.
36. a). Transfusion 41(Suppl)3s.
37. Busch MP, Dodd RY (2000) NAT and blood safety: what is the paradigm? Transfusion 40: 1157-1160.
38. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ (1996) The risk of transfusion-transmitted viral infections. N Engl J Med 334: 1685-1690.